ERBB family proteins have proven to be far more amenable to pharmacological inhibition than KRAS itself, and multiple ERBB inhibitors are approved for the treatment of cancers expressing mutant or amplified ERBB isoforms. The gene discussed is KRAS; the disease is cancer.